Clinical trials: Coronavirus Infections
Covid19, RSV Infection
Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test
Collection of Nasal Swabs, Throat Swabs and Saliva Samples from patients presenting at their designated care or testing facility displaying symptoms of either Influenza, Respiratory Syncytial Virus (RSV), SARS-CoV-2 or those who…
- Conditions
- Covid19, RSV Infection, Influenza Type A, Influenza Type B
- Trial name
- INFORM (NCT04782336)
- Testing
- Sample Collection
- Where
- 6 sites in United Kingdom
- Volunteers
- 79 people
- Sponsor
- LumiraDx UK Limited
Coronavirus Disease 2019 (COVID-19)
Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients
Multicenter double-blind placebo-controlled parallel-group randomized clinical trial of efficacy and safety of Raphamin in the treatment of coronavirus disease 2019 in outpatients.
- Trial name
- NCT05364671
- Testing
- Raphamin
- Where
- 36 sites in Russia
- Volunteers
- 771 people
- Sponsor
- Materia Medica Holding
COVID-19
Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198
This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.
- Trial name
- NCT04479644
- Testing
- BRII-198
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Brii Biosciences Limited
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, SARS-CoV-2
NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons
This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device.
- Conditions
- COVID-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04799392
- Testing
- NOWDx COVID-19 Test
- Where
- 5 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NOWDiagnostics, Inc.
Acute Respiratory Distress Syndrome
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Recent COVID 19 pandemic has overwhelmed health services all around the world, and humanity has yet to find a cure or a vaccine for the treatment of patients, mainly the severe ones, who pose a therapeutic challenge to healthcare…
- Trial name
- NCT04390152
- Testing
- Wharton's jelly derived Mesenchymal stem cells.
- Where
- 2 sites in Colombia
- Volunteers
- 6 people
- Sponsor
- BioXcellerator
COVID-19
Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
This study will measure the effect of FSD201 (ultramicronized PEA) + SoC vs placebo + SoC on Day 28, on disease progression in the confirmed coronavirus disease 2019 (COVID-19) patient population.
- Trial name
- NCT04619706
- Testing
- FSD201, Standard of Care for Covid-19
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Quantum Biopharma
Covid19
KAND567 Versus Placebo in Subjects Hospitalized With COVID-19
The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19 subjects in need of oxygen treatment.
- Trial name
- NCT06012565
- Testing
- KAND567, Microcrystalline cellulose
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 35 people
- Sponsor
- Novakand Pharma AB
COVID-19
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care (SoC) in participants hospitalized with coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04890509
- Testing
- Bemcentinib, SoC
- Where
- 12 sites in India, South Africa
- Volunteers
- 115 people
- Sponsor
- BerGenBio ASA
Postural Orthostatic Tachycardia Syndrome
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic…
- Trial name
- POTS (NCT05633407)
- Testing
- Efgartigimod
- Where
- 11 sites in United States
- Volunteers
- 53 people
- Sponsor
- argenx
COVID-19
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
The primary objective of this study is to evaluate efficacy of plitidepsin in pre-specified groups of immunocompromised patients with symptomatic COVID-19 requiring hospital care versus control in terms of mortality.
- Trial name
- NEREIDA (NCT05705167)
- Testing
- Plitidepsin
- Where
- 44 sites in Belgium, France and 9 more
- Volunteers
- 37 people
- Sponsor
- PharmaMar
COVID-19
Classification of COVID-19 Infection in Posteroanterior Chest X-rays
The objective of this study is to assess three configurations of two convolutional deep neural network architectures for the classification of COVID-19 PCX images.
- Trial name
- NCT04358536
- Testing
- CovX
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Dascena
Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19)
An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
This is an observational study in which data from people with cancer who had the Coronavirus disease 2019 (COVID-19) are collected and studied.
- Conditions
- Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19), SARS-CoV-2 Infection
- Trial name
- ROCURS (NCT05594147)
- Testing
- Non-TKIs, Other TKIs, Regorafenib (Stivarga, BAY73- 4506)
- Where
- United States
- Volunteers
- 4,103 people
- Sponsor
- Bayer
COVID-19
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.
- Trial name
- CCBCRISIS04 (NCT05166876)
- Testing
- Brequinar Sodium, Dipyridamole 75 MG
- Where
- 7 sites in India
- Volunteers
- 26 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19, Upper Respiratory Tract Infections
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours.
- Trial name
- NCT05252468
- Testing
- TaffiX™
- Where
- Bulgaria
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Covid19
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and…
- Trial name
- NCT04732468
- Testing
- hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
SARS-CoV-2 Infection
Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.
An open label, randomized, dose comparison, sequential cohorts study design in healthy volunteers (young adults) is a frequently used design in vaccine Phase 1 studies.
- Trial name
- NCT05385991
- Testing
- ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
- Where
- 6 sites in Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- ACM Biolabs
Mild-to-Moderate COVID-19
A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function
This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.
- Trial name
- NCT04486482
- Testing
- KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- Kaleido Biosciences
COVID-19
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19.
- Trial name
- NCT04362189
- Testing
- HB-adMSC
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hope Biosciences Research Foundation
SARS-CoV Infection
Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection
This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in individuals with mild COVID-19 Infection.
- Trial name
- NCT04443868
- Testing
- Nitric Oxide-Releasing Drug
- Sponsor
- Sanotize Research and Development corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.